GlassScriptPhysician profile
Kent T Ta
NPI 1508853003
$21,582.31
in general payments reported to CMS, 2019-2025
55 companies · $4,280 in 2025
The $4,280 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,831 · 2020: $2,102 · 2021: $2,124 · 2022: $2,321 · 2023: $4,037 · 2024: $3,887 · 2025: $4,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,938.47 |
| Education | $265.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,848.01 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $2,449.59 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,221.75 | 2019-2025 | Rinvoq, Humira |
| Pfizer INC. | $1,998.23 | 2019-2025 | |
| Ucb, INC. | $1,404.21 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,092.73 | 2019-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $1,070.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $991.52 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $917.13 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $898.74 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $840.28 | 2021-2025 | Saphnelo |
| Sobi, INC | $566.34 | 2019-2025 | |
| Tersera Therapeutics LLC | $453.49 | 2020-2025 | Quzyttir |
| Organon LLC | $427.31 | 2021-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $426.71 | 2019-2025 | Strensiq |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Ta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.